| 000 | 01730 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513153239.0 | ||
| 264 | 0 | _c19981209 | |
| 008 | 199812s 0 0 eng d | ||
| 022 | _a0952-3278 | ||
| 024 | 7 |
_a10.1016/s0952-3278(98)90088-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCarpio, L C | |
| 245 | 0 | 0 |
_aPhosphatidic acid effects on cytosolic calcium and proliferation in osteoblastic cells. _h[electronic resource] |
| 260 |
_bProstaglandins, leukotrienes, and essential fatty acids _cAug 1998 |
||
| 300 |
_a101-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_a1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCalcium _xmetabolism |
| 650 | 0 | 4 |
_aCalcium Channel Blockers _xpharmacology |
| 650 | 0 | 4 |
_aCalcium Signaling _xdrug effects |
| 650 | 0 | 4 |
_aCell Division _xdrug effects |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aCytoplasm _xmetabolism |
| 650 | 0 | 4 |
_aEpidermal Growth Factor _xpharmacology |
| 650 | 0 | 4 |
_aOsteoblasts _xcytology |
| 650 | 0 | 4 |
_aPhosphatidic Acids _xpharmacology |
| 650 | 0 | 4 |
_aPhospholipase D _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPropranolol _xpharmacology |
| 650 | 0 | 4 |
_aProtein Kinase C _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aSkull _xcytology |
| 650 | 0 | 4 |
_aSphingosine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aThapsigargin _xpharmacology |
| 650 | 0 | 4 |
_aVerapamil _xpharmacology |
| 700 | 1 | _aDziak, R | |
| 773 | 0 |
_tProstaglandins, leukotrienes, and essential fatty acids _gvol. 59 _gno. 2 _gp. 101-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0952-3278(98)90088-6 _zAvailable from publisher's website |
| 999 |
_c9738874 _d9738874 |
||